JPRN-UMIN000025537
Recruiting
未知
Examination of the epidemiology investigation in the rheumatoid arthritis new onset patient - Examination of the epidemiology investigation in the rheumatoid arthritis new onset patient
Division of Rheumatology, Takarazuka City Hospital.0 sites200 target enrollmentJanuary 6, 2017
ConditionsRheumatoid arthritis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Rheumatoid arthritis
- Sponsor
- Division of Rheumatology, Takarazuka City Hospital.
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with rheumatoid arthritis received some kind of treatments with DMARD.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Epidemiological Study to Evaluate the Prevalence and Progression of Diabetic Macular Ischemia in Patients with Diabetic Retinopathy Treated with Panretinal PhotocoagulatioJPRN-UMIN000042801Boehringer Ingelheim International GmbH539
Recruiting
Not Applicable
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR)Mutation Status in Non-Small Cell Lung Cancer (NSCLC) in India.Health Condition 1: null- Non Small Cell Lung CancerCTRI/2013/10/004077Roche Products India Pvt Ltd250
Completed
Not Applicable
A study to find out total number of Diabetic patients and Factors influencing it in our Kanyakumari district , its severity , associated health problems and how our behavioral modifications controls the same.CTRI/2019/09/021122RojaVanam Trust256
Recruiting
Not Applicable
RETROSPECTIVE OBSERVATIONAL STUDY OF BRAF AND PIK3CA MUTATION IN INDIAN PATIENTS WITH COLORECTAL CANCERâ??Health Condition 1: null- Colorectal CancerHealth Condition 2: C189- Malignant neoplasm of colon, unspecifiedCTRI/2016/06/006989Tata Memorial Hospital
Recruiting
Not Applicable
Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-upColorectal Cancer Stage IIColorectal Cancer Stage IIIDRKS00025104BioNTech SE1,500